Novo Nordisk has significantly reduced the US price of its diabetes medication Ozempic, dropping it from an estimated $135 per month to €69 per month. This move is expected to make the treatment more accessible to patients with type 2 diabetes in need of insulin replacement therapy.
Source: https://www.ft.com/content/825a4fb6-1f41-4f89-b2fb-5d344f48afa1